Latest Period
Q1 2026
Security Snapshot
Relay Therapeutics, Inc. - Common Stock, par value $0.001 per share (RLAY) Institutional Ownership
CUSIP: 75943R102
13F Institutional Holders and Ownership History from Q3 2020 to Q1 2026
Institutions Reporting
239
Shares (Excl. Options)
183,648,728
Price
$9.95
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock, par value $0.001 per share
- Symbol
- RLAY on Nasdaq
- Shares outstanding
- 4,389,099
- Price per share
- $12.57
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 183,648,728
- Total reported value
- $1,826,776,944
- % of total 13F portfolios
- 0%
- Share change
- +9,415,139
- Value change
- +$121,907,817
- Number of holders
- 239
- Price from insider filings
- $12.57
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- RLAY - Relay Therapeutics, Inc. - Common Stock, par value $0.001 per share is tracked under CUSIP 75943R102.
- 239 institutions reported positions in Q1 2026.
- 4 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 224 to 239 between Q4 2025 and Q1 2026.
- Reported value moved from $1,468,229,486 to $1,826,776,944.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 239 institutions filings for Q1 2026.
Investment Quick Answers
What is CUSIP 75943R102?
CUSIP 75943R102 identifies RLAY - Relay Therapeutics, Inc. - Common Stock, par value $0.001 per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q1 2026 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 75943R102:
Significant Owners of Relay Therapeutics, Inc. - Common Stock, par value $0.001 per share (RLAY) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Commodore Capital LP | 9.9% | +26% | $88,740,000 | +$19,053,000 | 17,000,000 | +27% | Commodore Capital LP | 30 Sep 2025 |
| Casdin Capital, LLC | 7.5% | $110,010,236 | 13,003,574 | CASDIN CAPITAL, LLC | 31 Dec 2025 | |||
| BlackRock, Inc. | 6.1% | -30% | $32,882,558 | -$13,928,338 | 10,308,012 | -30% | BlackRock, Inc. | 31 Mar 2025 |
| PERCEPTIVE ADVISORS LLC | 10% | +94% | $4,362,830 | -$89,215,124 | 438,471 | -95% | Perceptive Advisors LLC | 06 Apr 2026 |
As of 31 Mar 2026, 239 institutional investors reported holding 183,648,728 shares of Relay Therapeutics, Inc. - Common Stock, par value $0.001 per share (RLAY). This represents 4184% of the company’s total 4,389,099 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Relay Therapeutics, Inc. - Common Stock, par value $0.001 per share (RLAY) together control 3400% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| SB INVESTMENT ADVISERS (UK) LTD | 636% | 27,904,963 | 0% | 3.6% | $277,654,382 |
| Commodore Capital LP | 387% | 17,000,000 | 0% | 9.8% | $169,150,000 |
| Casdin Capital, LLC | 329% | 14,418,574 | +11% | 11% | $143,464,811 |
| BlackRock, Inc. | 296% | 12,975,299 | -1.9% | 0% | $129,104,225 |
| PERCEPTIVE ADVISORS LLC | 222% | 9,751,141 | +412% | 1.9% | $97,023,853 |
| Bellevue Group AG | 178% | 7,795,242 | -6.6% | 1.8% | $77,562,658 |
| VANGUARD CAPITAL MANAGEMENT LLC | 168% | 7,387,465 | 0% | 0% | $73,505,277 |
| STATE STREET CORP | 142% | 6,233,545 | -3% | 0% | $62,023,773 |
| Nextech Invest, Ltd. | 126% | 5,526,506 | +18% | 3.9% | $54,988,735 |
| TCG Crossover Management, LLC | 97% | 4,273,356 | +33% | 1.2% | $42,519,892 |
| FMR LLC | 84% | 3,695,431 | +2178% | 0% | $36,769,536 |
| GEODE CAPITAL MANAGEMENT, LLC | 80% | 3,510,636 | +3% | 0% | $34,938,159 |
| Balyasny Asset Management L.P. | 69% | 3,039,179 | +45% | 0.06% | $30,239,831 |
| Spruce Street Capital LP | 68% | 2,984,125 | 0% | 7.1% | $29,692,044 |
| DIMENSIONAL FUND ADVISORS LP | 67% | 2,940,536 | +19% | 0.01% | $29,248,486 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 59% | 2,590,000 | +418% | 0.04% | $25,770,500 |
| GOLDMAN SACHS GROUP INC | 58% | 2,541,861 | +37% | 0% | $25,291,517 |
| MPM BIOIMPACT LLC | 54% | 2,359,586 | +5.7% | 1.8% | $23,477,881 |
| BANK OF AMERICA CORP /DE/ | 44% | 1,937,695 | +86% | 0% | $19,280,066 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 44% | 1,924,938 | +17% | 0% | $19,154,000 |
| EcoR1 Capital, LLC | 43% | 1,904,762 | 0.81% | $18,952,382 | |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 42% | 1,863,565 | 0% | 0% | $18,542,472 |
| NORTHERN TRUST CORP | 38% | 1,675,387 | +47% | 0% | $16,670,101 |
| Alphabet Inc. | 36% | 1,564,173 | -0.29% | 0.39% | $15,563,521 |
| MORGAN STANLEY | 33% | 1,432,003 | -29% | 0% | $14,248,431 |
Institutional Holders of Relay Therapeutics, Inc. - Common Stock, par value $0.001 per share (RLAY) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 183,648,728 | $1,826,776,944 | +$121,907,817 | $9.95 | 239 |
| 2025 Q4 | 173,561,503 | $1,468,229,486 | +$55,238,266 | $8.46 | 224 |
| 2025 Q3 | 166,100,415 | $866,877,590 | -$18,449,389 | $5.22 | 195 |
| 2025 Q2 | 170,927,354 | $591,366,333 | +$36,190,035 | $3.46 | 203 |
| 2025 Q1 | 162,665,545 | $426,190,863 | -$16,276,230 | $2.62 | 205 |
| 2024 Q4 | 163,889,986 | $675,297,060 | -$42,360,167 | $4.12 | 197 |
| 2024 Q3 | 163,415,012 | $1,156,675,796 | +$253,277,512 | $7.08 | 193 |
| 2024 Q2 | 126,697,163 | $826,050,230 | -$42,426,305 | $6.52 | 171 |
| 2024 Q1 | 132,236,260 | $1,097,561,545 | +$24,572,655 | $8.30 | 182 |
| 2023 Q4 | 127,244,702 | $1,400,985,578 | -$17,110,979 | $11.01 | 176 |
| 2023 Q3 | 130,456,510 | $1,097,122,997 | -$2,918,566 | $8.41 | 169 |
| 2023 Q2 | 129,294,786 | $1,623,964,520 | -$20,848,790 | $12.56 | 159 |
| 2023 Q1 | 131,039,866 | $2,156,444,291 | +$53,163,179 | $16.47 | 155 |
| 2022 Q4 | 128,192,171 | $1,915,159,649 | +$58,936,160 | $14.94 | 163 |
| 2022 Q3 | 123,551,085 | $2,763,964,560 | +$25,518,843 | $22.37 | 153 |
| 2022 Q2 | 120,596,011 | $2,019,993,086 | +$124,571,798 | $16.75 | 137 |
| 2022 Q1 | 113,095,261 | $3,384,210,971 | +$67,735,824 | $29.93 | 133 |
| 2021 Q4 | 110,982,949 | $3,407,692,692 | +$588,792,014 | $30.71 | 128 |
| 2021 Q3 | 91,778,622 | $2,894,965,132 | +$74,331,777 | $31.53 | 132 |
| 2021 Q2 | 89,144,608 | $3,261,742,353 | +$138,052,473 | $36.59 | 124 |
| 2021 Q1 | 85,493,244 | $2,955,555,198 | -$171,240,328 | $34.57 | 135 |
| 2020 Q4 | 87,701,562 | $3,644,892,889 | +$108,159,345 | $41.56 | 115 |
| 2020 Q3 | 84,683,348 | $3,603,495,710 | +$3,603,495,710 | $42.59 | 94 |